ConductScience.org, home

Paper42549219

JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.

Liu X and 1 other. Front Immunol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration. Papers, record 42549219. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42549219

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.
PubMed
Journal
Front Immunol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu XXiaowei
2Wang YYang

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Janus Kinase 1Major topic
Inflammatory Bowel DiseasesMajor topic
Heterocyclic Compounds, 3-RingMajor topic
Janus Kinase InhibitorsMajor topic
Humans
Animals
Signal Transduction
Cytokines

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137423233Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.Lancet Gastroenterol Hepatol2023https://conductscience.org/library/papers/37423233PubMed
235907636Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.Gut2023https://conductscience.org/library/papers/35907636PubMed
329096949Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.Lancet2017https://conductscience.org/library/papers/29096949PubMed
436913180Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.Drugs2023https://conductscience.org/library/papers/36913180PubMed
535397241Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35397241PubMed
639147217Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.Clin Gastroenterol Hepatol2025https://conductscience.org/library/papers/39147217PubMed
737224198Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med2023https://conductscience.org/library/papers/37224198PubMed
838492903Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.Clin Gastroenterol Hepatol2024https://conductscience.org/library/papers/38492903PubMed
929104284JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nat Rev Drug Discov2017https://conductscience.org/library/papers/29104284PubMed
1036807832Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.Dig Dis Sci2023https://conductscience.org/library/papers/36807832PubMed
1134876680Revisiting fibrosis in inflammatory bowel disease: the gut thickens.Nat Rev Gastroenterol Hepatol2022https://conductscience.org/library/papers/34876680PubMed
1235081280Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med2022https://conductscience.org/library/papers/35081280PubMed
1335644166Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.Lancet2022https://conductscience.org/library/papers/35644166PubMed
1436720660IBD disease-modifying therapies: insights from emerging therapeutics.Trends Mol Med2023https://conductscience.org/library/papers/36720660PubMed
1539425738Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.Gastroenterology2024https://conductscience.org/library/papers/39425738PubMed
1640741688ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1.J Crohns Colitis2025https://conductscience.org/library/papers/40741688PubMed
1739572132AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.Gastroenterology2024https://conductscience.org/library/papers/39572132PubMed
1837923366Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Ann Rheum Dis2024https://conductscience.org/library/papers/37923366PubMed
1937932270Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts.Nat Commun2023https://conductscience.org/library/papers/37932270PubMed
2037231248Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease.Nat Rev Rheumatol2023https://conductscience.org/library/papers/37231248PubMed

See all 25 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42549219

GET https://conductscience.org/api/papers/v1/42549219/references?page=2